trending Market Intelligence /marketintelligence/en/news-insights/trending/PkprghKuu6cMLSErXFEy2g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aclaris drug candidate clears warts in second late-stage study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aclaris drug candidate clears warts in second late-stage study

Aclaris Therapeutics Inc. said its common warts' treatment, A-101 45% topical solution, was more effective than placebo in a second late-stage trial.

The Wayne, Pa.-based biopharmaceutical company's drug candidate was evaluated in a phase 3 trial, called THWART-1 and WART-301, against placebo, and achieved clinical and statistical significance in removing common warts.

A-101 45% topical solution, a high concentration hydrogen peroxide solution, met the main goal as well as all secondary efficacy goals of the study, the company said.

THWART-1 was the second late-stage study which evaluated A-101 45% topical solution to treat common warts. The previous phase 3 study, dubbed THWART-2, also achieved clinical and statistical significance in clearing common warts.

THWART-1 enrolled 503 patients with up to six warts at the start of the trial who self-administered the medicine or placebo twice a week for over a period of eight weeks. A higher proportion of patients who were treated with the medicine reported their warts had cleared by day 60.

No serious side-effects related to the treatment were reported.

Aclaris said the results from the studies will serve as a basis for a New Drug Application filing and will interest partners in seeking to commercialize the drug.

There are no FDA approved prescription treatments for common warts.